M Franken

1.2k total citations
53 papers, 690 citations indexed

About

M Franken is a scholar working on Economics and Econometrics, Oncology and Hematology. According to data from OpenAlex, M Franken has authored 53 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Economics and Econometrics, 18 papers in Oncology and 11 papers in Hematology. Recurrent topics in M Franken's work include Health Systems, Economic Evaluations, Quality of Life (30 papers), Pharmaceutical Economics and Policy (15 papers) and Multiple Myeloma Research and Treatments (11 papers). M Franken is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (30 papers), Pharmaceutical Economics and Policy (15 papers) and Multiple Myeloma Research and Treatments (11 papers). M Franken collaborates with scholars based in Netherlands, United States and United Kingdom. M Franken's co-authors include Carin A. Uyl‐de Groot, Marc Koopmanschap, Hedwig M. Blommestein, Pieter Sonneveld, Irina Cleemput, B Leeneman, Xander Koolman, Peter C. Huijgens, John B.A.G. Haanen and Siok Swan Tan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

M Franken

48 papers receiving 658 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Franken Netherlands 18 271 244 161 161 103 53 690
Hedwig M. Blommestein Netherlands 16 142 0.5× 296 1.2× 175 1.1× 253 1.6× 20 0.2× 62 665
Lisa L. Wood United States 9 170 0.6× 88 0.4× 50 0.3× 118 0.7× 83 0.8× 21 468
Jan Geißler United Kingdom 12 185 0.7× 110 0.5× 92 0.6× 111 0.7× 219 2.1× 48 786
John D. Sprandio United States 15 190 0.7× 371 1.5× 262 1.6× 47 0.3× 97 0.9× 27 989
R.D. Gelber Switzerland 18 144 0.5× 550 2.3× 129 0.8× 70 0.4× 29 0.3× 31 1.0k
J. Leonard Lichtenfeld United States 15 63 0.2× 282 1.2× 114 0.7× 86 0.5× 62 0.6× 24 679
C.A. Uyl-de Groot Netherlands 12 115 0.4× 258 1.1× 54 0.3× 118 0.7× 30 0.3× 28 553
Andrew Hantel United States 12 103 0.4× 119 0.5× 47 0.3× 123 0.8× 36 0.3× 60 499
Lisa Stevens United States 12 82 0.3× 327 1.3× 166 1.0× 33 0.2× 51 0.5× 26 676
Anne‐Gaëlle Le Corroller France 17 74 0.3× 323 1.3× 47 0.3× 306 1.9× 73 0.7× 44 718

Countries citing papers authored by M Franken

Since Specialization
Citations

This map shows the geographic impact of M Franken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Franken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Franken more than expected).

Fields of papers citing papers by M Franken

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Franken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Franken. The network helps show where M Franken may publish in the future.

Co-authorship network of co-authors of M Franken

This figure shows the co-authorship network connecting the top 25 collaborators of M Franken. A scholar is included among the top collaborators of M Franken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Franken. M Franken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilkinson, Mark D., Adrian Tassoni, António Atalaia, et al.. (2025). The FAIR journey of a patient-driven registry: Reflections and practical solutions from the Duchenne Data Platform FAIRification experience. Journal of Neuromuscular Diseases. 708690105–708690105.
2.
Franken, M, et al.. (2023). A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes. SHILAP Revista de lepidopterología. 4. 100095–100095. 2 indexed citations
3.
Leeneman, B, K. Schreuder, Carin A. Uyl‐de Groot, et al.. (2021). Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003–2018): A nationwide population-based study. European Journal of Cancer. 154. 111–119. 27 indexed citations
4.
Franken, M, B Leeneman, Maureen J.B. Aarts, et al.. (2021). Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open. 6(6). 100320–100320. 21 indexed citations
5.
Franken, M, et al.. (2019). A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer. 123. 58–71. 31 indexed citations
6.
Franken, M, Tim A. Kanters, J.L. Coenen, et al.. (2019). PCN330 A COMPARISON OF HEALTHCARE AND SOCIETAL COSTS OF HOSPITAL-BASED AND HOME-BASED SUBCUTANEOUS INJECTIONS OF TRASTUZUMAB. Value in Health. 22. S500–S500. 1 indexed citations
7.
Leeneman, B, M Franken, Veerle M.H. Coupé, et al.. (2019). Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. European Journal of Surgical Oncology. 45(5). 825–831. 21 indexed citations
8.
Franken, M, et al.. (2019). PNS143 PRIORITIZATION OF DRUGS FOR REIMBURSEMENT IN THE MALTESE HEALTH SYSTEM.. Value in Health. 22. S785–S785. 1 indexed citations
9.
Franken, M, Tim A. Kanters, Jules L.L.M. Coenen, et al.. (2018). Potential cost savings owing to the route of administration of oncology drugs. Anti-Cancer Drugs. 29(8). 791–801. 30 indexed citations
10.
Franken, M, et al.. (2015). A Triple Aim Framework For The Performance Assessment Of Disease Management Programs. Value in Health. 18(7). A400–A400. 1 indexed citations
11.
Franken, M, Carin A. Uyl‐de Groot, Ken Redekop, et al.. (2014). Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. Health Policy. 119(2). 186–194. 7 indexed citations
12.
Franken, M, Hedwig M. Blommestein, Peter C. Huijgens, et al.. (2014). Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib?. Value in Health. 17(2). 245–253. 7 indexed citations
13.
Franken, M & Xander Koolman. (2013). Health system goals: A discrete choice experiment to obtain societal valuations. Health Policy. 112(1-2). 28–34. 27 indexed citations
14.
Sandmann, Frank, M Franken, Adri Steenhoek, & Marc Koopmanschap. (2013). Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time. Health Policy. 112(3). 285–296. 6 indexed citations
15.
Franken, M, Siok Swan Tan, Ken Redekop, et al.. (2012). Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. Journal of Clinical Pharmacy and Therapeutics. 38(1). 41–47. 41 indexed citations
16.
Koopmanschap, Marc, Hans Severens, & M Franken. (2012). Internationale aspecten bij besluitvorming inzake geneesmiddelenvergoeding. Data Archiving and Networked Services (DANS). 97. 36–39. 1 indexed citations
17.
18.
Franken, M, Gepke O. Delwel, Wim Goettsch, et al.. (2012). Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands. European Journal of Cancer. 49(1). 8–16. 9 indexed citations
19.
Groot, Saskia de, Hedwig M. Blommestein, M Franken, & Carin A. Uyl‐de Groot. (2012). PCN154 Are Population-Based Registries a Suitable Tool for Outcomes Research in Cancer? Experiences from Four Registries. Value in Health. 15(7). A437–A438. 1 indexed citations
20.
Franken, M, et al.. (2010). Les systèmes de remboursement des médicaments. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hedwig M. Blommestein Breakdown of academic impact, for papers by Lisa L. Wood Breakdown of academic impact, for papers by Jan Geißler Breakdown of academic impact, for papers by John D. Sprandio Breakdown of academic impact, for papers by R.D. Gelber Breakdown of academic impact, for papers by J. Leonard Lichtenfeld Breakdown of academic impact, for papers by C.A. Uyl-de Groot Breakdown of academic impact, for papers by Andrew Hantel Breakdown of academic impact, for papers by Lisa Stevens Breakdown of academic impact, for papers by Anne‐Gaëlle Le Corroller
Rankless by CCL
2026